[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 23, 1996

Implantable Insulin Pump vs Multiple-Dose Insulin for Non—Insulin-Dependent Diabetes MellitusA Randomized Clinical Trial

Author Affiliations

for the Department of Veterans Affairs Implantable Insulin Pump Study Group
From the Johns Hopkins University School of Medicine, Baltimore, Md (Dr Saudek); the Omaha Veterans Affairs Medical Center and University of Nebraska Medical Center, Omaha (Dr Duckworth); the Cooperative Studies Program Coordinating Center, Hines (III) Veterans Affairs Medical Center (Ms Giobbie-Hurder and Dr Henderson); the San Diego Veterans Affairs Medical Center and University of California, San Diego (Drs Henry and Edelman); the Pittsburgh (Pa) Veterans Affairs Medical Center and University of Pittsburgh Medical Center (Dr Kelley); the Richmond (Va) Veterans Affairs Medical Center and Medical College of Virginia, Richmond (Drs Zieve and Adler); the Lexington (Ky) Veterans Affairs Medical Center and University of Kentucky, Lexington (Dr J. W. Anderson); the Omaha Veterans Affairs Medical Center and Creighton University, Omaha (Dr R. J. Anderson); the Baltimore Veterans Affairs Medical Center and University of Maryland, School; of Medicine, Baltimore (Drs Hamilton and Donner); the Durham Veterans Affairs Medical Center, Duke University, Durham, NC, and Indiana University School of Medicine, Indianapolis (Dr Kirkman); and the Cooperative Studies Program Central Research Pharmacy Coordinating Center, Albuquerque, NM (Ms Morgan).

JAMA. 1996;276(16):1322-1327. doi:10.1001/jama.1996.03540160044031
Abstract

Objective.  —To determine whether implantable insulin pump (IIP) therapy and multiple daily insulin (MDI) injections could equally attain improved blood glucose control, and to compare the 2 treatments with respect to reducing daily blood glucose fluctuations, reducing serious hypoglycemic insulin reactions, and improving patients' quality of life.

Design.  —Randomized clinical trial.

Setting.  —Seven Veterans Affairs medical centers.

Patients.  —One hundred twenty-one male type II diabetic patients between the ages of 40 and 69 years, receiving at least 1 injection of insulin per day and having hemoglobin A1c (HbA1c) levels of 8% or above.

Intervention.  —Intensive therapy (IIP or MDI) for 1 year.

Main Outcome Measures.  —Hemoglobin A1c and blood glucose levels.

Results.  —Blood glucose levels declined to 7.96±1.08 mmol/L (143.4±19.5 mg/dL) and 8.30±1.52 mmol/L (149.6±27.4 mg/dL) (mean ± SD) for IIP and MDI, respectively (P=.57). Hemoglobin A1c levels improved in both groups (time effect P<.001), to means of 7.54%±0.83% (MDI) vs 7.34%±0.79% (IIP). IIP reduced blood glucose fluctuations compared with MDI (P<.001), and reduced the incidence of mild clinical hypoglycemia by 68% (P<.001); IIP also eliminated the weight gain associated with MDI therapy and yielded better overall quality-of-life (P=.03) and impact-of-disease subscale scores (P=.05). Adverse events included 25% of subjects with episodes of insulin underdelivery due to microprecipitates of insulin within the pump.

Conclusions.  —Intensive insulin therapy with IIP and MDI is effective in controlling non—insulin-dependent diabetes mellitus. IIP has significant advantages in reducing glycemic variability, clinical hypoglycemia, and weight gain, while improving aspects of quality of life.

×